Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.9K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.9K
Neural Regulation01:37

Neural Regulation

44.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic deletion of adenosine A<sub>2A</sub> receptors attenuates memory deterioration and alterations of synaptic plasticity and metabolic controllers in the hippocampus and prefrontal cortex of aged mice.

GeroScience·2026
Same author

Neurophysiological In Vitro Model of Amyloid-β-Induced Deficits of Hippocampal LTP Involving Neuronal Adenosine A<sub>2A</sub> Receptor Dysfunction Through CD73.

Cells·2026
Same author

Aberrant adenosine A<sub>2A</sub> receptor signaling in the choroid plexus drives CSF hypersecretion and ventriculomegaly in hydrocephalus.

Nature communications·2025
Same author

The Rotenone-Induced Sporadic Parkinsonism Model: Timeline of Motor and Non-Motor Features.

The European journal of neuroscience·2025
Same author

Comparing adenosine A<sub>2A</sub> receptor modulation of cannabinoid CB<sub>1</sub> receptor-mediated inhibition of GABA and glutamate release in rodent striatal nerve terminals.

The European journal of neuroscience·2025
Same author

Impact of Glucocorticoid-Associated Stress-Like Conditions on Aquaporin-4 in Cultured Astrocytes and Its Modulation by Adenosine A<sub>2A</sub> Receptors.

Journal of neurochemistry·2025

Related Experiment Video

Updated: Mar 18, 2026

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
06:24

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

1.2K

How does adenosine control neuronal dysfunction and neurodegeneration?

Rodrigo A Cunha1,2

  • 1CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Journal of Neurochemistry
|July 2, 2016
PubMed
Summary
This summary is machine-generated.

Adenosine receptors (A1 R and A2A R) modulate brain information encoding and synaptic plasticity. Targeting these receptors, by blocking A2A R and activating A1 R, may offer maximal neuroprotection against brain insults.

Keywords:
A1 receptorA2A receptorastrocytemicrogliasynaptic plasticitysynaptotoxicity

More Related Videos

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.9K
Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.6K

Related Experiment Videos

Last Updated: Mar 18, 2026

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
06:24

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

1.2K
Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.9K
Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.6K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • The brain's adenosine modulation system primarily uses inhibitory A1 receptors (A1 R) and facilitatory A2A receptors (A2A R).
  • Adenosine release, triggered by neural activity, regulates synaptic transmission and information encoding, with A1 R inhibiting and A2A R facilitating plasticity in activated synapses.
  • Brain insults release adenosine and ATP, initially activating protective A1 R preconditioning, but prolonged activation leads to desensitization.

Purpose of the Study:

  • To elucidate the dual role of adenosine receptors in synaptic function and their implications in brain injury.
  • To investigate how brain insults alter adenosine receptor expression and function, leading to neurodegeneration.
  • To explore the potential of combined A1 R and A2A R modulation for maximal neuroprotection.

Main Methods:

  • Review of existing literature on adenosine receptor function in synaptic plasticity and brain injury models.
  • Analysis of adenosine and ATP release dynamics during neural activity and brain insults.
  • Examination of the signaling pathways and cellular targets of A2A R in neuronal, astrocytic, and microglial cells.

Main Results:

  • Brain insults up-regulate A2A R, which, despite potentially aiding adaptive plasticity, exacerbates brain damage by promoting excitotoxicity.
  • A2A R blockade demonstrates neuroprotection in models of epilepsy, depression, Alzheimer's, and Parkinson's disease.
  • Simultaneous enhancement of A1 R preconditioning and inhibition of excessive A2A R function is proposed as a strategy for maximal neuroprotection.

Conclusions:

  • The adenosine system's physiological role sharpens information encoding, but its dysregulation during brain insults contributes to pathology.
  • While A1 R offer initial protection, their desensitization and the up-regulation of detrimental A2A R shift the balance towards neurodegeneration.
  • Targeting both A1 R and A2A R offers a promising therapeutic avenue for mitigating brain damage and enhancing recovery.